When the FDA made the decision to give Johnson & Johnson’s diabetes drug Invokana a black box warning in 2017, one would like to believe that the decision was not made lightly. The boxed warning is the strongest warning the agency can issue for a drug on the US healthcare market and indicates that the product can pose grave risks to the consumer if used. There is ...
Patients taking Invokana and other SGLT2 inhibitors to treat and control their Type II diabetes have done so with the risk of a wide variety of adverse side effects for quite some time. The drugs’ links to serious conditions like bone fractures, kidney failure, and a particularly dangerous condition known as ketoacidosis are well established. They can strike anyone – young, old, men, and women.
However, there is read more.... --> continue reading...
The analysis is in: people are less likely to buy a medication when they’ve been warned that it may increase the odds of them having their leg or foot amputated. And, while this is bad news for Invokana specifically, Forbes would like you to know that Johnson & Johnson – the drug’s manufacturer – will be just fine.
This is the gist of an article that appeared on the ...
continue reading...Known as SGLT2 inhibitors for short, sodium glucose co-transporter 2 inhibitors are a class of drugs intended for certain individuals with Type II diabetes. The drugs prevent glucose from being absorbed in the kidneys and reduce glucose in the blood by causing it to be expelled in the urine.
Unfortunately, this relatively new class of drugs has already allegedly caused enough ...
continue reading...
